Aarkstore Enterprise-Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

The industry analysis specialist, has released its new report, “Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global ADHD market. The report identifies the key trends shaping and driving the global ADHD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ADHD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimated the ADHD market to be worth $3.82 billion in 2009 and it is forecast to remain stable with a very low growth of a CAGR of 0.2% annually for the next seven years, to reach $3.88 billion by 2017. This modest growth can be primarily attributed to population growth and increased prescription rates. However, a low treatment seeking rate, low diagnosis rate, combined with the availability of alternate options such as generics, behavioral and psychological therapies, diet changes, as well as the unknown cause of the disease, continue to pose significant challenges for prospective market entrants.

Scope

The report provides information on the key drivers and challenges of the ADHD market. Its scope includes:
- Annualized global ADHD market revenues data from 2001 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as serotonin reuptake inhibitors, neuronal nicotine receptors agonists, dopamine reuptake inhibitors, AMPA type glutamate receptors.
- Analysis of the current and future competition in the global ADHD market. Key market players covered are Sceile Pharma, AstraZeneca, Supernus Pharma, Cortex pharma.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ADHD therapeutics market.


For more information, please contact :
http://www.aarkstore.com/reports/Attention-Deficit-Hyperactivity-Disorder-ADHD-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017-40555.html

Related Reports
Disease and Therapy Review: Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, Q1, 2011

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, Q1 2011

Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, Q4, 2010

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, Q4 2010

Was this helpful? 0 0 Comments

Did this article Aarkstore Enterprise-Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics solve your question / problem? If not, read following similar tutorials & articles or ask a new question.

• Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Aarkstore Enterprise?

  Aarkstore announce a new report "Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017" through its vast collection of...

You're reading Aarkstore Enterprise-Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics.